{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:33Z","timestamp":1790915013430,"version":"4.1.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation, leading to growth in kidney volume and renal function decline. Although therapies have emerged, there is still an important unmet need for slowing the rate of disease progression in ADPKD. High intracellular levels of adenosine 3\u2032,5\u2032-cyclic monophosphate (cAMP) are involved in cell proliferation and fluid secretion, resulting in cyst formation. Somatostatin (SST), a hormone that is involved in many cell processes, has the ability to inhibit intracellular cAMP production. However, SST itself has limited therapeutic potential since it is rapidly eliminated in vivo. Therefore analogues have been synthesized, which have a longer half-life and may be promising agents in the treatment of ADPKD. This review provides an overview of the complex physiological effects of SST, in particular renal, and the potential therapeutic role of SST analogues in ADPKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfz054","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T15:10:50Z","timestamp":1551712250000},"page":"1306-1316","source":"Crossref","is-referenced-by-count":29,"title":["Somatostatin in renal physiology and autosomal dominant polycystic kidney disease"],"prefix":"10.1093","volume":"35","author":[{"given":"A Lianne","family":"Messchendorp","sequence":"first","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F","family":"Casteleijn","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"key":"2021020410064165600_gfz054-B1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021020410064165600_gfz054-B2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2005","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021020410064165600_gfz054-B3","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.3748\/wjg.v19.i35.5775","article-title":"Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases","volume":"19","author":"Abu-Wasel","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2021020410064165600_gfz054-B4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1432-2277.2011.01360.x","article-title":"Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study","volume":"24","author":"van Keimpema","year":"2011","journal-title":"Transpl Int"},{"key":"2021020410064165600_gfz054-B5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2015.39","article-title":"Vasopressin and disruption of calcium signalling in polycystic kidney disease","volume":"11","author":"Chebib","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2021020410064165600_gfz054-B6","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2021020410064165600_gfz054-B7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2021020410064165600_gfz054-B8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","article-title":"Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease","volume":"96","author":"Mancinelli","year":"2016","journal-title":"Lab Invest"},{"key":"2021020410064165600_gfz054-B9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021020410064165600_gfz054-B10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1210\/endo-83-4-783","article-title":"Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro","volume":"83","author":"Krulich","year":"1968","journal-title":"Endocrinology"},{"key":"2021020410064165600_gfz054-B11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF01212214","article-title":"Evidence for an inhibitor of insulin release in the pancreatic islets","volume":"5","author":"Hellman","year":"1969","journal-title":"Diabetologia"},{"key":"2021020410064165600_gfz054-B12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"2021020410064165600_gfz054-B13","first-page":"267","volume-title":"The Handbook of Physiology, the Endocrine Pancreas and Regulation of Metabolism","author":"Patel","year":"1999"},{"key":"2021020410064165600_gfz054-B14","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1073\/pnas.80.22.6932","article-title":"High-resolution chromosomal localization of human genes for amylase, proopiomelanocortin, somatostatin, and a DNA fragment (D3S1) by in situ hybridization","volume":"80","author":"Zabel","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021020410064165600_gfz054-B15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"2021020410064165600_gfz054-B16","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/endo-109-6-1943","article-title":"Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat","volume":"109","author":"Patel","year":"1981","journal-title":"Endocrinology"},{"key":"2021020410064165600_gfz054-B17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI114055","article-title":"Circulating prosomatostatin-derived peptides. Differential responses to food ingestion","volume":"83","author":"Ensinck","year":"1989","journal-title":"J Clin Invest"},{"key":"2021020410064165600_gfz054-B18","first-page":"E428","article-title":"Circulating forms of somatostatinlike immunoreactivity in human plasma","volume":"250","author":"Shoelson","year":"1986","journal-title":"Am J Physiol"},{"key":"2021020410064165600_gfz054-B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"2021020410064165600_gfz054-B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0167-0115(96)00136-X","article-title":"Somatostatin expression in human renal cortex and mesangial cells","volume":"68","author":"Turman","year":"1997","journal-title":"Regul Pept"},{"key":"2021020410064165600_gfz054-B21","first-page":"F1095","article-title":"Human proximal tubular epithelial cells express somatostatin: regulation by growth factors and cAMP","volume":"274","author":"Turman","year":"1998","journal-title":"Am J Physiol"},{"key":"2021020410064165600_gfz054-B22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"2021020410064165600_gfz054-B23","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","article-title":"Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney","volume":"280","author":"Balster","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021020410064165600_gfz054-B24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","article-title":"Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues","volume":"120","author":"Unger","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2021020410064165600_gfz054-B25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1535370218803893","article-title":"The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease","volume":"243","author":"Lin","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"2021020410064165600_gfz054-B26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.1984.tb03470.x","article-title":"Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin","volume":"21","author":"Jones","year":"1984","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021020410064165600_gfz054-B27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2265.1988.tb01199.x","article-title":"Effect of a new somatostatin analogue SMS 201-995 (Sandostatin) on the renin-aldosterone axis","volume":"28","author":"Sieber","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021020410064165600_gfz054-B28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1042\/cs0840455","article-title":"Somatostatin as a modulator of distal nephron water permeability","volume":"84","author":"Ray","year":"1993","journal-title":"Clin Sci"},{"key":"2021020410064165600_gfz054-B29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/(SICI)1097-4644(19961215)63:4<410::AID-JCB3>3.0.CO;2-W","article-title":"Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth","volume":"63","author":"Hatzoglou","year":"1996","journal-title":"J Cell Biochem"},{"key":"2021020410064165600_gfz054-B30","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1046\/j.1523-1755.2002.00320.x","article-title":"Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release","volume":"61","author":"Schmidt","year":"2002","journal-title":"Kidney Int"},{"key":"2021020410064165600_gfz054-B31","first-page":"8","article-title":"Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats","volume":"7","author":"Winkler","year":"1982","journal-title":"Miner Electrolyte Metab"},{"key":"2021020410064165600_gfz054-B32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.1988.31","article-title":"Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin","volume":"33","author":"Ishikawa","year":"1988","journal-title":"Kidney Int"},{"key":"2021020410064165600_gfz054-B33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"2021020410064165600_gfz054-B34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"2021020410064165600_gfz054-B35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"2021020410064165600_gfz054-B36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2021020410064165600_gfz054-B37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0168-8278(00)80377-3","article-title":"Regulation and deregulation of cholangiocyte proliferation","volume":"33","author":"Alvaro","year":"2000","journal-title":"J Hepatol"},{"key":"2021020410064165600_gfz054-B38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2021020410064165600_gfz054-B39","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","article-title":"Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors","volume":"23","author":"Giustina","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"2021020410064165600_gfz054-B40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Meijer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2021020410064165600_gfz054-B41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Saf"},{"key":"2021020410064165600_gfz054-B42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"2021020410064165600_gfz054-B43","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032, 5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"2021020410064165600_gfz054-B44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"2021020410064165600_gfz054-B45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/zeb.2012.0825","article-title":"The zebrafish as a model to study polycystic liver disease","volume":"10","author":"Tietz Bogert","year":"2013","journal-title":"Zebrafish"},{"key":"2021020410064165600_gfz054-B46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"2021020410064165600_gfz054-B47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021020410064165600_gfz054-B48","doi-asserted-by":"crossref","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","article-title":"Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease","volume":"12","author":"Kugita","year":"2017","journal-title":"PLoS One"},{"key":"2021020410064165600_gfz054-B49","doi-asserted-by":"crossref","first-page":"16618.e1-2","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"2021020410064165600_gfz054-B50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2021020410064165600_gfz054-B51","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2021020410064165600_gfz054-B52","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"2021020410064165600_gfz054-B53","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","author":"Gevers","year":"2015","journal-title":"Liver Int"},{"key":"2021020410064165600_gfz054-B54","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"2021020410064165600_gfz054-B55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021020410064165600_gfz054-B56","author":"Hogan","year":"2017"},{"key":"2021020410064165600_gfz054-B57","year":"2018"},{"key":"2021020410064165600_gfz054-B58","year":"2017"},{"key":"2021020410064165600_gfz054-B59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021020410064165600_gfz054-B60","doi-asserted-by":"crossref","first-page":"e32533","DOI":"10.1371\/journal.pone.0032533","article-title":"Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study","volume":"7","author":"Ruggenenti","year":"2012","journal-title":"PLoS One"},{"key":"2021020410064165600_gfz054-B61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000256657","article-title":"Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease","volume":"31","author":"Orskov","year":"2010","journal-title":"Am J Nephrol"},{"key":"2021020410064165600_gfz054-B62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2013.03.030","article-title":"Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations","volume":"62","author":"Spithoven","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2021020410064165600_gfz054-B63","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2021020410064165600_gfz054-B64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2021020410064165600_gfz054-B65","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/BF03345632","article-title":"Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study","volume":"31","author":"Auriemma","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2021020410064165600_gfz054-B66","first-page":"227","article-title":"Pasireotide: a novel treatment for patients with acromegaly","volume":"10","author":"Cuevas-Ramos","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2021020410064165600_gfz054-B67","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol"},{"key":"2021020410064165600_gfz054-B68","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/8\/1306\/36192998\/gfz054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/8\/1306\/36192998\/gfz054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T06:29:08Z","timestamp":1612765748000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/8\/1306\/5481118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4,27]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz054","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,1]]},"published":{"date-parts":[[2019,4,27]]}}}